Experienced chief financial officer brings deep financial and strategic leadership to Latigo’s board of directors Appointment supports continued operational growth THOUSAND OAKS, Calif. — April 8, 2026 — Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to developing innovative…
Veteran biotech leader with more than 15 years of experience joins as Latigo advances non-opioid pain pipeline Appointment comes as Latigo builds toward late-stage development and broader corporate milestones THOUSAND OAKS, Calif. — March 3, 2026 — Latigo Biotherapeutics, Inc…
Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins Latigo’s board Proceeds support advancement of company’s Nav1.8 inhibitor clinical programs and development of broader pipeline THOUSAND OAKS, Calif. – March 17, 2025 – Latigo…
LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in Phase 1 trial Fast Track designation will facilitate development and expedited regulatory review of LTG-001 THOUSAND OAKS, Calif., March 3, 2025 – Latigo Biotherapeutics (“Latigo”) today announced the U.S…
Former Horizon Therapeutics chairman & CEO brings 30 years of biopharmaceutical industry experience Walbert led recent acquisition of Horizon Therapeutics by Amgen for $28.3 billion THOUSAND OAKS, Calif., November 19, 2024 – Latigo Biotherapeutics (“Latigo”), a clinical-stage biotechnology company developing…
Potential best-in-class non-opioid Nav1.8 inhibitor, LTG-305 aims to provide safer treatment for chronic pain by targeting underlying mechanisms of pain at its source Trial will evaluate safety, tolerability, and pharmacokinetics of LTG-305 in healthy volunteers through single- and multiple-ascending dose…
Former William Blair partner and group head, Lugo has facilitated raising more than $6 billion in capital through 40-plus transactions, including IPOsVeteran venture capitalists Drs. Seidenberg and Tananbaum will help scale and accelerate the development of Latigo’s pipeline of non-opioid…
Positive Phase 1 results for LTG-001, Latigo’s potential best-in-class non-opioid Nav1.8 inhibitor, demonstrated it to be well tolerated with rapid absorptionDr. Singla brings world-class expertise in analgesics, pain management, and clinical development to accelerate Company’s pipeline of non-opioid pain medicinesOpioid…
Farzan brings more than two decades’ leadership experience with a strong track record in fundraising and IPOs THOUSAND OAKS, Calif. – July 22, 2024 – Latigo Biotherapeutics Inc. (“Latigo”), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target…
Discovery and development of new molecules directed against validated pain targets is required to advance the treatment of pain disorders.